甲磺酸伊马替尼治疗慢性粒细胞白血病的临床效果及其对免疫功能的影响

摘要

Objective To observe the clinical effect of imatinib mesylate in the treatment of chronic myelocytic leukemia and its influence on immunologic function. Methods 50 patients with chronic myelocytic leukemia treated in our hospital from February 2009 to February 2014 were selected as research objects,and were divided into control group and observation group by throwing dice.Conventional treatment was provided to control group,while oral adminis-tration of imatinib mesylate was applied to observation group.The curative effect,adverse reaction,and changes of im-munologic function on T cell before and after treatment was compared. Results Remission rate and incidence of adverse reactions in the observation group was 96.0% and 8.0% respectively,compared with 76.0% and 32.0% in the control group,the difference was significant (P<0.05).After treatment,CD3+[(1435.7±300.3)/μl v s (1102.5±287.6)/μl],CD4+[(786.5±156.2)/μl v s (700.1±100.8)/μl],and CD4+/CD8+ [(1.60±0.46) v s (1.20±0.41)] in observation group and control group had significant difference (P<0.05). Conclusion Imatinib mesylate is safe and effective in the treatment of chronic myelocytic leukemia and can effectively improve its immunologic function.%目的：观察甲磺酸伊马替尼治疗慢性粒细胞血管病的临床效果及其对免疫功能的影响。方法选择本院2009年2月~2014年2月收治的50例慢性粒细胞白血病患者为研究对象，掷骰子将其分为对照组和观察组，对照组患者行常规化疗治疗，观察组患者行甲磺酸伊马替尼口服治疗。比较两组的疗效、不良反应及治疗前后T细胞免疫功能变化。结果观察组缓解率、不良反应发生率分别为96.0%、8.0%，与对照组的76.0%、32.0%比较，差异有统计学意义(P<0.05)。观察组和对照组治疗后的CD3+[(1435.7±300.3)个/μl v s(1102.5±287.6)个/μl]、CD4+[(786.5±156.2)个/μl vs(700.1±100.8)个/μl]、CD4+/CD8+[(1.60±0.46) vs(1.20±0.41)]比较，差异有统计学意义(P<0.05)。结论甲磺酸伊马替尼治疗慢性粒细胞血管病安全有效，能有效改善其免疫功能。